학술논문

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
Document Type
Article
Source
In The Lancet Oncology August 2023 24(8):881-891
Subject
Primary Research
Articles
Language
ISSN
1470-2045